Pfizer in India

Pfizer in India is as old as the republic; we launched our operations here in 1950 and listed Pfizer Limited on the Bombay Stock Exchange in 1966. It an end-to-end pharma company with unparalleled manufacturing, R&D and commercial presence.

Our Presence

ZOPHL JV with Zydus

- 70 lakh vials capacity
- 350 FTE
- Injectable cytotoxic drugs



Manufacturing - Local

- 400 crore tablets capacity
- 150 FTE
- Oral Solids & Steroids

Manufacturing Export

- 22 crore vials capacity
- 2000 FTE
- Sterile Injectable
- Investment of ~$400 Mn

Service Centre

GPD	GRA	R&D	WWD	Other Services
320 FTE	~300 FTE	~200 FTE	~100 FTE	~150 FTE
Clinical Development Support	Regulatory Process	Lab Based R&D	Safety Reporting	Manufacturing BT/Finance/ Medical

Focus therapies

Vaccines

Protecting people from potentially life-threatening pneumococcal diseases with a vaccine that makes an impact across all stages of life. Since launch, we have supplied over ~11.5 mn doses of our Pneumococcal conjugate vaccine to the people of India

Internal medicines

Diverse portfolio across seven therapy areas and 17 specialties with strong presence across respiratory, multi-vitamins, gastrointestinal, neuroscience, cardiovascular, pain management and women's healthcare

Oncology

Offering breakthrough therapies for cancers of the breast, lung, genito-urinary and blood

Rare diseases

Innovative therapies for various rare diseases, including hematology and growth disorders

Hospitals/Anti-infectives

Large and diverse portfolio of anti-infectives with therapies that help address the greatest unmet medical needs including treatment of invasive fungal and resistant bacterial infections

Inflammation and immunology

Bringing new and advanced approaches to target inflammation in patients suffering from chronic diseases related to the immune system

Our purpose

Breakthroughs that change Patients' Lives

Our CSR priorities

Fostering young Indian minds in innovations in healthcare; curbing AMR in time; unburdening cancer patients and working towards community development

Disease Awareness & access to healthcare

- Cancer Care Program with Tata Trusts
- Pediatric Cancer Fund with ImpaCCT Foundation at TMH
- Project Aastha Helpdesk with Doctors For You
- Ummeed Helpdesk with VCare Foundation
- Upskilling for Arogramitras withTISS-NHA
- Train the Trainer Program with can support

Support national healthcare priorities & programs

- Expansion of Antimicrobial Stewardship Program with ICMR
- Online learning platform with Americares

Support healthcare innovations in India

- Pfizer IIT Delhi Innovation & IP Program
- Pfizer INDovation Program

Health, sanitation & community development

- Holistic village transformation with BAIF

Disaster relief

- COVID-19 response

Our India Patient Charter

Listen

Make patient insights an integral part of our operational strategy

Act

Deliver easier and faster access to Pfizer innovative therapies

Empower

Partners and support patient organizations

Bringing breakthroughs with focused R&D

Global Product Development Center, Chennai

1. Over 650 researchers and clinicians
2. Supports clinical as well as late-stage development of medicines and regulatory affairs across all therapeutic areas in Pfizer.
3. Presently conducting ~25 clinical studies over 300 patients

Global Drug Development Center, IIT Madras Research Park

1. 250+ scientists
2. Consolidates Pfizer's lab-based development capabilities, focusing on product innovations, API development and injectable finished dosage development
3. Global innovation and drug development in anti-inectives,oncolytics, sterile injectables, anesthesia and CNS

Efforts to ensure and accelerate access

At Pfizer, we prioritize the need to make our life-changing products accessible for people across India and we do this through:

1. Determining India-specific pricing
2. Disseminating patient assistance programs across the lifecycle
3. Partnering and participating in government programs and agendas
4. Working with institutions involved in community development
5. Going beyond affordability to enable access through the Ummeed program